重组人碱性磷酸酶对脓毒症相关急性肾损伤患者7天肌酐清除率的影响:一项随机临床试验
STOP-AKI试验为国际多中心随机双盲安慰剂对照适应性2a/2b期研究,纳入301例脓毒症相关急性肾损伤成人患者。比较不同剂量重组人碱性磷酸酶与安慰剂,主要终点为第1至7天肌酐清除率AUC,结果显示1.6 mg/kg组与安慰剂组差异无统计学意义。
要点
- 重组人碱性磷酸酶1.6 mg/kg未显著改善脓毒症相关AKI患者短期肾功能。
- 各组致死性与非致死性严重不良事件发生率均有报告,需进一步评估其他临床结局。
核心结论
- 在脓毒症相关急性肾损伤危重患者中,与安慰剂相比,重组人碱性磷酸酶未显著改善短期肾功能。
研究设计与样本
- STOP-AKI为国际多中心(53个招募中心)、随机、双盲、安慰剂对照、剂量探索、适应性2a/2b期研究,纳入301例成人脓毒症相关AKI患者。
- 患者于2014年12月至2017年5月入组,随访90天,最终随访日期为2017年8月14日。
- 试验第1部分将患者随机分配至0.4 mg/kg(n=31)、0.8 mg/kg(n=32)、1.6 mg/kg(n=29)或安慰剂(n=30),每日一次,连续3天,以确定最佳剂量。
- 基于建模方法和不良事件,最佳剂量确定为1.6 mg/kg;第2部分比较1.6 mg/kg(n=82)与安慰剂(n=86)。
主要发现
- 第1至7天,1.6 mg/kg组中位肌酐清除率从26.0 mL/min(IQR 8.8至59.5)增至65.4 mL/min(IQR 26.7至115.4)。
- 第1至7天,安慰剂组中位肌酐清除率从35.9 mL/min(IQR 12.2至82.9)增至61.9 mL/min(IQR 22.7至115.2)。
- 致死性不良事件发生率:0.4 mg/kg组26.3%、0.8 mg/kg组17.1%、1.6 mg/kg组17.4%、安慰剂组29.5%。
- 非致死性严重不良事件发生率:0.4 mg/kg组21.0%、0.8 mg/kg组14.3%、1.6 mg/kg组25.7%、安慰剂组20.5%。
临床怎么用
- 对于脓毒症相关急性肾损伤危重患者,重组人碱性磷酸酶1.6 mg/kg每日一次连续3天未显示短期肾功能获益,不应据此常规使用。
局限性
- 研究结论限于短期肾功能终点,需进一步研究评估其他临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sepsis-associated acute kidney injury (AKI) adversely affects long-term kidney outcomes and survival. Administration of the detoxifying enzyme alkaline phosphatase may improve kidney function and survival. OBJECTIVE: To determine the optimal therapeutic dose, effect on kidney function, and adverse effects of a human recombinant alkaline phosphatase in patients who are critically ill with sepsis-associated AKI. DESIGN, SETTING, AND PARTICIPANTS: The STOP-AKI trial was an international (53 recruiting sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b study in 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and AKI. Patients were enrolled between December 2014 and May 2017, and follow-up was conducted for 90 days. The final date of follow-up was August 14, 2017. INTERVENTIONS: In the intention-to-treat analysis, in part 1 of the trial, patients were randomized to receive recombinant alkaline phosphatase in a dosage of 0.4 mg/kg (n = 31), 0.8 mg/kg (n = 32), or 1.6 mg/kg (n = 29) or placebo (n = 30), once daily for 3 days, to establish the optimal dose. The optimal dose was identified as 1.6 mg/kg based on modeling approaches and adverse events. In part 2, 1.6 mg/kg (n = 82) was compared with placebo (n = 86). MAIN OUTCOMES AND MEASURES: The primary end point was the time-corrected area under the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide a mean daily creatinine clearance (AUC1-7 ECC). Incidence of fatal and nonfatal (serious) adverse events ([S]AEs) was also determined. RESULTS: Overall, 301 patients were enrolled (men, 70.7%; median age, 67 years [interquartile range {IQR}, 59-73]). From day 1 to day 7, median ECC increased from 26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to 115.4) in the recombinant alkaline phosphatase 1.6-mg/kg group vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR, 22.7 to 115.2) in the placebo group (absolute difference, 9.5 mL/min [95% CI, -23.9 to 25.5]; P = .47). Fatal adverse events occurred in 26.3% of patients in the 0.4-mg/kg recombinant alkaline phosphatase group; 17.1% in the 0.8-mg/kg group, 17.4% in the 1.6-mg/kg group, and 29.5% in the placebo group. Rates of nonfatal SAEs were 21.0% for the 0.4-mg/kg recombinant alkaline phosphatase group, 14.3% for the 0.8-mg/kg group, 25.7% for the 1.6-mg/kg group, and 20.5% for the placebo group. CONCLUSIONS AND RELEVANCE: Among patients who were critically ill with sepsis-associated acute kidney injury, human recombinant alkaline phosphatase compared with placebo did not significantly improve short-term kidney function. Further research is necessary to assess other clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02182440.
引用
- Pickkers P, Mehta RL, Murray PT, et al. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2018. PMID: 30357272. doi:10.1001/jama.2018.14283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。